Immunization with DnaJ (hsp40) could elicit protection against nasopharyngeal colonization and invasive infection caused by different strains of Streptococcus pneumoniae

Vaccine

Volumn 29, Issue 9, 2011, Pages 1736-1744

  Cui, Yali ^a   Zhang, Xuemei ^a   Gong, Yi ^a   Niu, Siqiang ^a   Yin, Nanlin ^a   Yao, Run ^a   Xu, Wenchun ^a   Li, Dairong ^a   Wang, Hong ^a   He, Yujuan ^a   Cao, Ju ^a   Yin, Yibing ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

DnaJ; Immunization; Streptococcus pneumoniae; Vaccine

Indexed keywords

GAMMA INTERFERON; HEAT SHOCK PROTEIN 40; INTERLEUKIN 10; INTERLEUKIN 17; PLASMID DNA; PNEUMOCOCCUS VACCINE; PROTEIN DNAJ; RECOMBINANT DNAJ PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; CLONING; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; IMMUNIZATION; INFECTION PREVENTION; MOUSE; NASOPHARYNX; NONHUMAN; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTEIN PURIFICATION; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 79952709493     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.126     Document Type: Article

References (46)

1. Parsons HK, Metcalf SC, Tomlin K, Read RC, Dockrell DH. Invasivepneumococcal disease and the potential for prevention by vaccination in the United Kingdom. J Infect 2007;54:435-8.
2. Greene CM, Kyaw MH, Ray SM, Schaffner W, Lynfield R, Barrett NL, et al. Preventability of invasive pneumococcal disease and assessment of current polysaccharide vaccine recommendations for adults: United States, 2001-2003. Clin Infect Dis 2006;43:141-50.
3. Shah P, Briles DE, King J, Hale Y, Swiatlo E. Mucosal Immunization with Polyamine Transport Protein D (PotD) protects mice against nasopharyngeal colonization with Streptococcus pneumoniae. Exp Biol Med 2009;234:403-9.
4. World Health Organization. Pneumococcal vaccines[position paper]. Wkly Epidemiol Rec 1999;74:177-83.
5. Fedson DS. The clinical effectiveness of pneumococcal vaccination: a brief review. Vaccine 1999;17:85-90.
6. Eskola J. Immunogenicity of pneumococcal conjugate vaccines. Pediatr Infect Dis J 2000;19:388-93.
7. Moore MR, Whitney CG. Emergence of nonvaccine serotypes following introduction of pneumococcal conjugate vaccine: cause and effect? Clin Infect Dis 2008;46:183-5.
8. Swiatlo E, Ware D. Novel vaccine strategies with protein antigens of Streptococcus pneumoniae. FEMS Immunol Med Microbiol 2003;38:1-7.
9. Giefing C, Meinke AL, Hanner M, Henics T, Bui MD, Gelbmann D, et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med 2008;205:117-31.
10. Khan MN, Bansal A,Shukla D,Paliwal P,Sarada SKS, Mustoori SR, etal. Immunogenicity and protective efficacy of DnaJ (hsp40) of Streptococcus pneumoniae against lethal infection in mice. Vaccine 2006;24:6225-31.
11. He ChF, Lin ZY. Pneumococcal Vac 2005;28:765-72.
12. López R. Streptococcus pneumoniae and its bacteriophages: one long argument. Int Microbiol 2004;7:163-71.
13. Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004;4: 144-54.
14. Novak R, Henriques B, Charpentier E, Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 1999;399:590-3.
15. Cao J, Li DR, Gong Y, Yin NL, Chen TM, Wong CK, et al. Caseinolytic protease: a protein vaccine which could elicit serotype-independent protection against invasive pneumococcal infection. Clin Exp Immunol 2009;156:52-60.
16. Spratt BG,Greenwood BM. Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet 2000;356:1210-1.
17. Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 2007;3:1628-36.
18. Porat N, Barkai G, Jacobs MR, Trefler R, Dagan R. Four antibiotic resistant Streptococcus pneumoniae clones unrelated to the pneumococcal conjugate vaccine serotypes, including 2 new serotypes, causing acute otitis media in southern Israel. J Infect Dis 2004;189:385-92.
19. Bogaert D, Hermans PW, Adrian PV, Rümke HC, de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine 2004;22:2209-20.
20. Pelton SI, Dagan R, Gaines BM, Klugman KP, Laufer D, O'Brien K, et al. Pneumococcal conjugate vaccines: proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine 2003;21:1562-71.
21. Heeg C, Franken C, vander Linden M, Al-LahhamA, Reinert RR. Genetic diversity of pneumococcal surface protein A of Streptococcus pneumoniae meningitis in German children. Vaccine 2007;25:1030-5.
22. Hollingshead SK, Becker R, Briles DE. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 2000;68:5889-900.
23. Balachandran P, Brooks-Walter A, Virolainen-Julkunen A, Hollingshead SK, Briles DE. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun 2005;70:2526-34.
24. Gor DO, Ding X, Briles DE, Jacobs MR, Greenspan NS. Relationship between surface accessibility for PpmA PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae. Infect Immun 2005;73:1304-12.
25. Zügel U, Kaufmann SHE. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev 1999;12:19-39.
26. Cheetham ME, Caplan AJ. Structure, function and evolution of DnaJ: conservation and adaptation of chaperone function. Cell Stress Chaperones 1998;3:28-36.
27. Morsczeck C, Prokhorova T, Sigh J, Pfeiffer M, Bille-Nielsen M, Petersen J, et al. Streptococcus pneumoniae: proteomics of surface proteins for vaccine development. Clin Microbiol Infect 2008;14:74-81.
28. Wu HY,Virolainen A,Mathews B,King J,Russell MW, Briles DE. Establishment of a Streptococcus pneumoniae nasopharyngeal colonization model in adult mice. Microb Pathog 1997;23:127-37.
29. Briles DE, Crain MJ, Gray BM, Forman C, Yother J. Strong association between capsular type and virulence for mice among human isolates of Streptococcus pneumoniae. Infect Immun 1992;60:111-6.
30. van Ginkel FW, McGhee JR, Watt JM, Campos-Torres A, Parish LA, Briles DE. Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection. Proc Natl Acad Sci USA 2003;100:14363-7.
31. Del Giudice G. Hsp70: a carrier molecule with built-in adjuvanticity. Experientia 1994;50:1061-6.
32. Cao J, Chen TM, Li DR, Wong CK, Chen DP, Xu WC, et al. Mucosal immunization with purified ClpP could elicit protective efficacy against pneumococcal pneumonia and sepsis in mice. Microb Infect 2008;10:1536-42.
33. Mizrachi Nebenzahl Y, Bernstein A, Portnoi M, Shagan M, Rom S, Porgador A, et al. Streptococcus pneumoniae surface-exposed glutamyl tRNA synthetase, a putative adhesin, is able to induce a partially protective immune response in mice. J Infect Dis 2007;196:945-53.
34. Cao J, Gong Y, Li DR, Yin NL, Chen TM, Xu WC, et al. CD4+ T lymphocytes mediated protection against invasive pneumococcal infection induced by mucosal immunization with ClpP and CbpA. Vaccine 2009;27:2838-44.
35. Ferreira DM, Darrieux M, Oliveira ML, Leite LC, Miyaji EN. Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein a is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production. Clin Vaccine Immunol 2008;15:499-505.
36. Ferreira DM, Darrieux M, Silva DA, Leite LCC, Ferreira Jr JMC, Ho PL, et al. Characterization of protective mucosal and systemic immune responses elicited by Pneumococcal Surface Proteins PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol 2009;16:636-45.
37. Hvalbye BK, Aaberge IS, Løvik M, Haneberg B. Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect Immun 1999;67:4320-5.
38. Meng JP, Yin YB, Zhang XM, Huang YS, Lan K, Cui F, et al. Identificationof Streptococcus pneumoniae genes specifically induced in mouse lung tissues. Can J Microbiol 2008;54:58-65.
39. Claverys JP, Dintilhac A, Pestova EV, Martin B, Morrison DA. Construction and evaluationofnewdrug-resistance cassettes for gene disruption mutagenesisin Streptococcus pneumoniae, using an ami test platform. Gene 1995;164:123-8.
40. Roche AM, King SJ, Weiser JN. Live attenuated Streptococcus pneumoniae strains induce serotype-independent mucosal and systemic protection in mice. Infect Immun 2007;75:2469-75.
41. Pasetti MF, Salerno-Gonç alves R, Sztein MB. Mechanisms of adaptive immunity that prevent colonization at mucosal surfaces. ASM Press; 2005. pp. 35-47.
42. Robertson GT, Ng WL, Foley J, Gilmour R, Winkler ME. Global transcriptional analysis of ClpP mutations of type 2 Streptococcus pneumoniae and their effects on physiology and virulence. J Bacteriol 2002;184:3508-20.
43. Minami Y, Höhfeld J, Ohtsuka K, Hartl FU. Regulation of the heat-shock protein 70 reaction cycle by the mammalian DnaJ homolog Hsp40. J Biol Chem 1996;271:19617-24.
44. Qiu XB, Shao YM, Miao S, Wang L. he diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci 2006;63:2560-70.
45. Mestecky J, Russell MW, Elson CO. Intestinal IgA: novel views on its function in the defence of the largest mucosal surface. Gut 1999;44:2-5.
46. Malley R, Trzcinski K, Srivastava A, Thompson CM, Anderson PW, Lipsitch M. CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci USA 2005;102:4848-53.